I just sent you a PM here in your I Hub mailbox. Now everyone let's focus on all the AMBS DD. There were a couple great alerts out this weekend on AMBS I had posted earlier. I will post them again now. Here is one. AMBS on fire AMARANTUS BIOSCIENCES, INC. (OTC: AMBS) PENNY STOCK ON FIRE!
AMBS explodes on the OTCBB! Update: Since Amarantus Biosciences Inc. (OTC: AMBS) made its spectacular run from well under a penny to recent highs near $0.09 the stock dropped to lows of $0.03 before exploding up again on massive volume.Now moving to the upside on accelerated trading volume investors are wondering if AMBS can regain its previous highs.
On November 9 RBCC and Amarantus BioSciences, Inc. have finalized the framework of their proposed joint venture (JV) and expect to execute material definitive agreements within 30 days, subject to closing documents. The JV's first priority will be to advance Amarantus' NuroPro Parkinson's Diagnostic Blood Test ("NuroPro") towards commercialization. NuroPro works by identifying differentiated levels of proteins and peptides in the blood of patients who have Parkinson's disease, versus those who do not. On November 6 AMBS announced that it has appointed Amgen Co-Founder Joseph Rubinfeld, PhD to its Corporate Advisory Board. Dr. Rubinfeld will assist management in positioning the Company's development programs for partnering, as well as provide guidance on MANF-based small molecule strategies with his extensive medicinal chemistry background. "I believe in MANF," said Dr. Rubinfeld, "I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen"
To get the inside scoop on AMBS subscribe to OTCMagic.com right now. Also everyone should know, we have something HUGE coming!
Amarantus BioSciences, Inc. is a California-based biotechnology company founded in January 2008 under the name Jumpkicks, Inc. In June of 2011 the Company changed their name to Amarantus Therapeutics, Inc., and put their focus on developing their intellectual property and proprietary technology to develop drug candidates to treat human disease. AMBS own the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF”). MANF is a protein that corrects protein misfolding. Protein misfolding is one of the major causes of apoptosis (cell death). This property provides a compelling rationale for the research and development of MANF-based products as therapeutics for human disease. Our lead MANF product development effort is centered on a therapy for Parkinson’s disease. On November 1st they announced that they intend to pursue the identification of one or multiple therapeutic indications for its lead therapeutic candidate MANF that could lead to the therapy receiving orphan drug designation(s) with the Food and Drug Administration (FDA)
Conclusion: AMBS has seen some important developments over the last few months the likes of which are rarely seen on the OTCBB and still trades at a low market valuation. The stock is technically sound and still trades very close to its historical lows. While AMBS stock is still quite cheap they have developed the type of loyal following can catapult these pennies to 1,000% + gains. All this Makes AMBS a stock to watch and might just provide a spectacular trade opportunity in the weeks and months ahead! We have something HUGE coming! Subscribe right now or you will miss it!
News 
Market Data 
Discover 
